Artisan Partners Limited Partnership Grows Stock Position in Tarsus Pharmaceuticals, Inc. $TARS

Artisan Partners Limited Partnership boosted its position in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 3.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 558,326 shares of the company’s stock after buying an additional 19,023 shares during the quarter. Artisan Partners Limited Partnership’s holdings in Tarsus Pharmaceuticals were worth $33,181,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also bought and sold shares of TARS. Osaic Holdings Inc. lifted its holdings in shares of Tarsus Pharmaceuticals by 779.1% in the 2nd quarter. Osaic Holdings Inc. now owns 2,778 shares of the company’s stock worth $113,000 after acquiring an additional 2,462 shares during the last quarter. Tower Research Capital LLC TRC grew its holdings in Tarsus Pharmaceuticals by 220.3% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,045 shares of the company’s stock valued at $164,000 after purchasing an additional 2,782 shares during the last quarter. West Wealth Group LLC purchased a new stake in Tarsus Pharmaceuticals in the 3rd quarter worth about $202,000. Valeo Financial Advisors LLC purchased a new stake in Tarsus Pharmaceuticals in the 3rd quarter worth about $209,000. Finally, XTX Topco Ltd bought a new stake in Tarsus Pharmaceuticals in the second quarter worth about $227,000. Institutional investors own 90.01% of the company’s stock.

Insider Transactions at Tarsus Pharmaceuticals

In other news, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction dated Wednesday, December 24th. The shares were sold at an average price of $82.51, for a total value of $495,060.00. Following the completion of the sale, the chief executive officer owned 857,991 shares in the company, valued at approximately $70,792,837.41. The trade was a 0.69% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Dianne C. Whitfield sold 7,397 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The stock was sold at an average price of $80.10, for a total transaction of $592,499.70. Following the completion of the sale, the insider directly owned 38,958 shares of the company’s stock, valued at $3,120,535.80. The trade was a 15.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 8.97% of the stock is owned by corporate insiders.

Key Tarsus Pharmaceuticals News

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Guggenheim set a new $90.00 price target for TARS, signaling confidence in long-term upside if the company executes on growth drivers. Guggenheim Price Target
• Positive Sentiment: Oppenheimer issued a favorable forecast for Tarsus’ stock, which may provide support if sentiment shifts back toward growth expectations. Oppenheimer Forecast
• Positive Sentiment: Tarsus announced management will participate in upcoming investor conferences — an opportunity to update investors on commercialization progress and future guidance. Investor Conferences Release
• Neutral Sentiment: Analysis pieces are debating whether the market has rerated TARS too cautiously after adoption headlines for XDEMVY, offering a counterpoint to the negative analyst actions but not delivering hard new catalysts. Yahoo Analysis
• Negative Sentiment: HC Wainwright sharply reduced near-term and multi-year EPS forecasts (Q1–Q4 2026 and FY2026–FY2029), cutting assumptions for revenue/earnings ramp — this is the primary downward pressure on the shares today. HC Wainwright Estimates Summary
• Negative Sentiment: Zacks Research downgraded TARS from “strong-buy” to “hold,” which can trigger selling from momentum/quant funds and heighten near-term caution among retail investors. Zacks Downgrade

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Oppenheimer upped their target price on Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a research note on Wednesday. Barclays started coverage on Tarsus Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $100.00 price objective for the company. Mizuho started coverage on Tarsus Pharmaceuticals in a research report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 price objective on the stock. Zacks Research downgraded Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research note on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $87.00.

Tarsus Pharmaceuticals Stock Down 0.5%

Shares of NASDAQ:TARS opened at $75.52 on Friday. The business’s 50 day moving average is $72.00 and its 200 day moving average is $68.73. The stock has a market cap of $3.21 billion, a P/E ratio of -46.62 and a beta of 0.57. Tarsus Pharmaceuticals, Inc. has a 52-week low of $38.51 and a 52-week high of $85.25. The company has a quick ratio of 4.25, a current ratio of 3.85 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The firm had revenue of $151.67 million during the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative return on equity of 19.63% and a negative net margin of 14.72%. Sell-side analysts predict that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.